SOURCE: Morria Biopharmaceuticals Plc

Morria Biopharmaceuticals Plc

February 19, 2013 08:30 ET

Morria Pharmaceuticals Announces Quotation for Trading on the OTC Bulletin Board

NEW YORK, NY--(Marketwire - Feb 19, 2013) -  Morria Biopharmaceuticals Plc (OTCQB: MRRBY) (the "Company"), an emerging growth biopharmaceutical company focused on developing novel first-in-class, synthetic, multi-functional non-steroidal anti-inflammatory drugs, announced today that its American Depositary Shares ("ADSs") representing its ordinary shares have commenced trading on the OTC Bulletin Board in the United States under the ticker symbol MRRBY.

To enable the trading of Morria's ordinary shares in the United States, the Company's ordinary shares must be deposited with Deutsche Bank Trust Company Americas, the Company's depositary bank for its American Depositary Receipt (ADR) program. Each ADS represents two ordinary shares of the Company.

Mark Cohen, Executive Chairman of Morria, commented, "The commencement of trading of our securities in the U.S. is an important step for Morria and positions us for broad and diversified investor exposure. As we move forward with clinical development of our product candidates, we believe that having our ADSs publicly traded in the U.S. will help us in meeting our financing needs."

The quotation of Morria's ADSs on the OTC Bulletin Board has been approved by the Financial Industry Regulatory Authority, Inc. ("FINRA"). In November of 2012, the Company became a publicly reporting company under the US Securities Exchange Act of 1934, as amended, by filing a Form 20-F Registration Statement with the US Securities Exchange Commission (SEC). A Form F-6 Registration Statement for the registration of the Company's ADSs has been declared effective by the SEC.

About Morria Biopharmaceuticals

Morria Biopharmaceuticals is an emerging growth biopharmaceutical company focused on the development of first-in-class, multi-functional non-steroidal, synthetic anti-inflammatory drugs. Morria has developed a class of synthetic drugs termed MFAIDs (Multi-Functional Anti-Inflammatory Drugs) representing a new class and therapeutic platform for the treatment of a wide range of inflammatory diseases such as allergies and autoimmune diseases. Morria currently has two lead product candidates in its clinical pipeline, both of which have completed first-in-patient clinical studies: MRX-4, a nasal spray for treating allergic rhinitis (hay fever), and MRX-6, a topical cream for treating contact dermatitis (a common type of eczema); and pre-clinical programs in ophthalmology, cystic fibrosis, and inflammatory bowel disease. Morria's business strategy is to expand and build a biopharmaceutical business to focus on a spectrum of inflammatory diseases based on its current and upcoming first-in-class product candidates, that will address the current unmet need for safe and potent alternatives to steroids.

Forward Looking Statement Safe Harbor
This press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms including "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would," "hope," "look forward" and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You should not put undue reliance on any forward-looking statements. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements.

Contact Information